Protagonist Therapeutics (PTGX) Revenue & Revenue Breakdown
Protagonist Therapeutics Revenue Highlights
Latest Revenue (Y)
$60.00M
Latest Revenue (Q)
$4.17M
Main Segment (Y)
License and Collaboration Agreement
Main Geography (Y)
License and Collaboration Agreement
Protagonist Therapeutics Revenue by Period
Protagonist Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $60.00M | 125.73% |
| 2022-12-31 | $26.58M | -2.84% |
| 2021-12-31 | $27.36M | -4.44% |
| 2020-12-31 | $28.63M | 12293.07% |
| 2019-12-31 | $231.00K | -99.25% |
| 2018-12-31 | $30.93M | 54.14% |
| 2017-12-31 | $20.06M | 100.00% |
| 2016-12-31 | - | 100.00% |
| 2015-12-31 | - | 100.00% |
| 2014-12-31 | - | - |
Protagonist Therapeutics generated $60.00M in revenue during NA 2023, up 125.73% compared to the previous quarter, and up 194.02% compared to the same period a year ago.
Protagonist Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $4.17M | -98.37% |
| 2024-03-31 | $254.95M | 324.92% |
| 2023-12-31 | $60.00M | 100.00% |
| 2023-09-30 | - | 100.00% |
| 2023-06-30 | - | 100.00% |
| 2023-03-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2022-09-30 | - | -100.00% |
| 2022-06-30 | $859.00K | -96.66% |
| 2022-03-31 | $25.72M | 198.50% |
| 2021-12-31 | $8.62M | -16.23% |
| 2021-09-30 | $10.29M | 354.13% |
| 2021-06-30 | $2.27M | -63.40% |
| 2021-03-31 | $6.19M | 9.54% |
| 2020-12-31 | $5.65M | -56.92% |
| 2020-09-30 | $13.11M | 110.94% |
| 2020-06-30 | $6.22M | 70.47% |
| 2020-03-31 | $3.65M | 34.13% |
| 2019-12-31 | $2.72M | -34.34% |
| 2019-09-30 | $4.14M | -150.57% |
| 2019-06-30 | $-8.19M | -624.94% |
| 2019-03-31 | $1.56M | -33.70% |
| 2018-12-31 | $2.35M | -61.53% |
| 2018-09-30 | $6.12M | -47.60% |
| 2018-06-30 | $11.67M | 8.28% |
| 2018-03-31 | $10.78M | -4.44% |
| 2017-12-31 | $11.28M | 28.48% |
| 2017-09-30 | $8.78M | 100.00% |
| 2017-06-30 | - | 100.00% |
| 2017-03-31 | - | 100.00% |
| 2016-12-31 | - | 100.00% |
| 2016-09-30 | - | 100.00% |
| 2016-06-30 | - | 100.00% |
| 2016-03-31 | - | 100.00% |
| 2015-12-31 | - | 100.00% |
| 2015-09-30 | - | 100.00% |
| 2015-06-30 | - | 100.00% |
| 2015-03-31 | - | - |
Protagonist Therapeutics generated $4.17M in revenue during Q2 2024, up -98.37% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
Protagonist Therapeutics Revenue Breakdown
Protagonist Therapeutics Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|
| License and Collaboration Agreement | $18.60M | - | - |
| License And Collaborative Revenue | - | $28.60M | $200.00K |
| Financial Service Other | - | $1.50M | - |
Protagonist Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 21: License and Collaboration Agreement (100.00%).
Quarterly Revenue by Product
| Product/Service | Mar 24 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Mar 19 | Sep 18 | Jun 18 | Mar 18 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Development Services | $900.00K | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| License and Collaboration Agreement | - | $900.00K | $25.70M | $10.60M | - | - | - | - | - | - | - | - | - | - | - |
| License And Service | - | - | - | - | $8.00M | - | - | - | - | - | - | - | - | - | - |
| License And Collaborative Revenue | - | - | - | - | - | $95.80M | $96.30M | $6.60M | $99.40M | $113.90M | $113.60M | $1.60M | $6.10M | $11.67M | $10.78M |
| Financial Service Other | - | - | - | - | - | $200.00K | $600.00K | $500.00K | $500.00K | $500.00K | - | - | - | - | - |
Protagonist Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Mar 24: Development Services (100.00%).
Protagonist Therapeutics Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|
| License and Collaboration Agreement | $18.60M | - | - |
| License And Collaborative Revenue | - | $28.60M | $200.00K |
| Financial Service Other | - | $1.50M | - |
Protagonist Therapeutics's latest annual revenue breakdown by geography, as of Dec 21: License and Collaboration Agreement (100.00%).
Quarterly Revenue by Country
| Country | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Mar 19 | Sep 18 | Jun 18 | Mar 18 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| License and Collaboration Agreement | $900.00K | $25.70M | $10.60M | - | - | - | - | - | - | - | - | - | - | - |
| License And Service | - | - | - | $8.00M | - | - | - | - | - | - | - | - | - | - |
| License And Collaborative Revenue | - | - | - | - | $95.80M | $96.30M | $6.60M | $99.40M | $113.90M | $113.60M | $1.60M | $6.10M | $11.67M | $10.78M |
| Financial Service Other | - | - | - | - | $200.00K | $600.00K | $500.00K | $500.00K | $500.00K | - | - | - | - | - |
Protagonist Therapeutics's latest quarterly revenue breakdown by geography, as of Jun 22: License and Collaboration Agreement (100.00%).
Protagonist Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| ARVN | Arvinas | $78.50M | $76.50M |
| PTGX | Protagonist Therapeutics | $60.00M | $4.17M |
| MRUS | Merus | $43.95M | $7.33M |
| RLAY | Relay Therapeutics | $25.55M | - |
| IDYA | IDEAYA Biosciences | $23.39M | - |
| HOOK | HOOKIPA Pharma | $20.13M | - |
| RVMD | Revolution Medicines, Inc. Warrant | $11.58M | - |
| RNA | Avidity Biosciences | $9.56M | $2.04M |
| STOK | Stoke Therapeutics | $8.78M | $4.22M |
| PLRX | Pliant Therapeutics | $1.58M | - |
| BDTX | Black Diamond Therapeutics | - | - |
| XFOR | X4 Pharmaceuticals | - | $563.00K |
| DAWN | Day One Biopharmaceuticals | - | $8.19M |
| ABOS | Acumen Pharmaceuticals | - | - |
| VRNA | Verona Pharma | - | - |
| CERE | Cerevel Therapeutics | - | - |
| REPL | Replimune Group | - | - |
| KURA | Kura Oncology | - | - |
| SNDX | Syndax Pharmaceuticals | - | $3.50M |
| TERN | Terns Pharmaceuticals | - | - |
| VTYX | Ventyx Biosciences | - | - |
| AKRO | Akero Therapeutics | - | - |
PTGX Revenue FAQ
What is Protagonist Therapeutics’s yearly revenue?
Protagonist Therapeutics's yearly revenue for 2023 was $60M, representing an increase of 125.73% compared to 2022. The company's yearly revenue for 2022 was $26.58M, representing a decrease of -2.84% compared to 2021. PTGX's yearly revenue for 2021 was $27.36M, representing a decrease of -4.44% compared to 2020.
What is Protagonist Therapeutics’s quarterly revenue?
Protagonist Therapeutics's quarterly revenue for Q2 2024 was $4.17M, a -98.37% decrease from the previous quarter (Q1 2024), and a 0% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $254.95M, a 324.92% increase from the previous quarter (Q4 2023), and a 0% increase year-over-year (Q1 2023). PTGX's quarterly revenue for Q4 2023 was $60M, a 100.00% increase from the previous quarter (Q3 2023), and a 0% increase year-over-year (Q4 2022).
What is Protagonist Therapeutics’s revenue growth rate?
Protagonist Therapeutics's revenue growth rate for the last 3 years (2021-2023) was 119.32%, and for the last 5 years (2019-2023) was 25874.03%.
What are Protagonist Therapeutics’s revenue streams?
Protagonist Therapeutics's revenue streams in c 21 are License and Collaboration Agreement
What is Protagonist Therapeutics’s main source of revenue?
For the fiscal year ending Dec 21, the largest source of revenue of Protagonist Therapeutics was License and Collaboration Agreement. This segment made a revenue of $18.6M, representing 100.00% of the company's total revenue.